3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
89
Leukemia
68
Precursor Cell Lymphoblastic Leukemia-Lymphoma
36
Lymphoma
26
Leukemia, Erythroblastic, Acute
19
Leukemia, Myelomonocytic, Acute
18
Leukemia, Monocytic, Acute
18
Leukemia, Megakaryoblastic, Acute
18
Congenital Abnormalities
13
Burkitt Lymphoma
13
Lymphoma, Large B-Cell, Diffuse
12
Myelodysplastic Syndromes
10
Lymphoma, Non-Hodgkin
10
Anemia, Refractory, with Excess of Blasts
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Lymphoma, Follicular
6
Leukemia, Myelomonocytic, Chronic
6
Leukemia, Myeloid, Chronic-Phase
6
Leukemia, Eosinophilic, Acute
6
Recurrence
5
Myeloproliferative Disorders
5
Lymphoma, Large-Cell, Immunoblastic
5
Leukemia, Promyelocytic, Acute
5
Leukemia, Biphenotypic, Acute
5
Leukemia, Basophilic, Acute
5
Hodgkin Disease
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasms
4
Myelodysplastic-Myeloproliferative Diseases
4
Multiple Myeloma
4
Interventions
pirtobrutinib
5
Lenalidomide
4
Rituximab
3
Imatinib Mesylate
3
ruxolitinib
2
ponatinib
2
ibrutinib
2
Platelet Transfusion
2
Brentuximab Vedotin
2
Bortezomib
2
Bendamustine Hydrochloride
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
zanubrutinib
1
vosaroxin
1
venetoclax
1
nilotinib
1
idelalisib
1
bosutinib
1
acalabrutinib
1
Zoledronic Acid
1
Vorinostat
1
Vincristine
1
Tretinoin
1
Prednisone
1
Plasma Exchange
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Exercise
1
Doxorubicin
1
Dexamethasone
1
Denosumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Hematologic Diseases
×
Cytarabine
×
Clear all
NCT01191801
2018-08-22
VALOR
Sunesis Pharmaceuticals
Phase 3
Completed
711 enrolled
15 charts